# PT-141 FAQ: Common Questions Answered (Bremelanotide)

> PT-141 FAQ: what it is, how bremelanotide works, what the trials measured, the label dosage, and the regulatory status — direct, cited answers to the most common questions.

Plain answers on bremelanotide — mechanism, effects, dosage, and regulatory status — each tied to the cited evidence.

## How big is the effect of bremelanotide on sexual desire?

Real but modest. The two Phase 3 RECONNECT trials (n=1,267 premenopausal women with HSDD) found bremelanotide 1.75 mg subcutaneous as-needed improved FSFI-desire by an integrated +0.35 (P<.001) and reduced desire-related distress by an integrated −0.33 (P<.001) over 24 weeks [3]. The effect is statistically significant and reproducible, but small by the scale of the instruments — the central point of recent critical re-analyses [12].

## Does PT-141 cause weight loss?

PT-141 is not a weight-loss drug and is not approved for any metabolic use. Because MC4R also sits in appetite circuits, high-frequency dosing in early Phase 1 research affected caloric intake and body weight [2]. That is a pharmacological observation, not an approved or recommended use, and it appeared at dosing far beyond the approved as-needed regimen [7].

## Why is PT-141 being studied with a PDE-5 inhibitor?

Because the two work through different routes and might be complementary. PT-141 acts centrally on melanocortin receptors; a PDE-5 inhibitor acts peripherally on blood flow [1]. In June 2024 the developer announced a Phase 2 study of bremelanotide co-administered with a PDE-5 inhibitor for men with erectile dysfunction who do not respond to PDE-5-inhibitor monotherapy [8]. This program is investigational, not approved [8].

## What is PT-141?

PT-141 is the research name for bremelanotide, a synthetic cyclic heptapeptide that activates central melanocortin receptors (MC3R and MC4R) to influence sexual desire [1]. It is an analogue of the natural peptide alpha-MSH [1]. It was FDA-approved in 2019 for HSDD in premenopausal women [7].

## What is PT-141 peptide?

The PT-141 peptide is a cyclic heptapeptide lactam (a seven-amino-acid ring) with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, molecular weight 1025.2 Da, and CAS number 189691-06-3 [1]. Its ring structure makes it more stable than linear melanocortin peptides, which helped it become a viable drug [1].

## What does the PT-141 peptide do?

It activates melanocortin receptors in the brain. By stimulating MC4R in hypothalamic circuits tied to sexual motivation, PT-141 is thought to engage dopamine pathways governing desire [1]. In trials it improved sexual desire in premenopausal women with HSDD [3], and in animals it produced erectile activity and activated hypothalamic neurons [1].

## What is PT-141 used for?

Its one approved use is treating acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women [7]. Every other use — in men, in postmenopausal women, or for performance — is off-label or research-grade and not FDA-approved [7][9].

## Is PT-141 the same as bremelanotide?

Yes. PT-141 is the research and development name; bremelanotide is the international nonproprietary name for the same compound [1]. The FDA approved it as bremelanotide injection in 2019 [7]. Material sold as a "PT-141 research chemical" is the same molecule by name but is not the regulated, approved product [7].

## What is bremelanotide?

Bremelanotide is a melanocortin-receptor agonist — a synthetic peptide that activates MC3R and MC4R in the central nervous system to influence sexual desire [1]. It is the FDA-approved drug name for the compound also known as PT-141, approved in 2019 for HSDD in premenopausal women [7].

## How does PT-141 work?

Through the brain, not blood flow. PT-141 activates MC4R (and secondarily MC3R) in hypothalamic and limbic circuits, including the medial preoptic area, engaging dopamine pathways that govern sexual motivation [1]. This central mechanism is what distinguishes it from PDE-5 inhibitors, which act on vascular smooth muscle [1].

## What receptors does PT-141 act on?

Chiefly the melanocortin-4 receptor (MC4R), with secondary activity at MC3R — both concentrated in the central nervous system [1]. It also activates MC1R in skin, which is the basis for the hyperpigmentation reported with repeated frequent dosing [7].

## Does PT-141 work through the brain or through blood flow?

Through the brain. PT-141 acts centrally on melanocortin receptors in hypothalamic circuits governing sexual motivation [1]. A 2022 fMRI study confirmed it alters central brain processing of erotic stimuli [5]. PDE-5 inhibitors, by contrast, act peripherally on blood flow — a fundamentally different mechanism [1].

## What is a melanocortin receptor agonist?

A melanocortin receptor agonist is a compound that activates the melanocortin receptors (MC1R–MC5R), a family of cell switches that respond to peptides like alpha-MSH [1]. PT-141 is one such agonist, acting mainly on the central MC3R and MC4R subtypes [1].

## Does PT-141 increase testosterone?

No. PT-141 does not act through the hormonal axis that controls testosterone and does not directly raise it [1]. This is a common misconception. It works on central melanocortin receptors, not on testosterone production — a mechanism unrelated to hormone levels [1].

## How is PT-141 different from PDE-5 inhibitors?

By mechanism and site of action. PT-141 acts centrally, on brain melanocortin receptors that govern sexual desire [1]. PDE-5 inhibitors act peripherally, relaxing vascular smooth muscle to improve blood flow [1]. PT-141 addresses desire; PDE-5 inhibitors address the physical erectile response — which is why combining them is being studied [8].

## What is the PT-141 dosage?

The approved label dose of bremelanotide is 1.75 mg subcutaneously, as needed, with a maximum of one dose per 24 hours and no more than eight doses per month, for HSDD in premenopausal women [7]. This is a documented label figure for the approved use, not a recommendation for any individual.

## How much PT-141 should I take?

This site gives no individual dosing advice. The FDA-labeled dose for the approved drug bremelanotide is 1.75 mg subcutaneous as-needed for premenopausal women with HSDD, with strict frequency limits [7]. Any decision about use belongs with a qualified prescriber, not a website.

## How much PT-141 to inject?

The prescribing information specifies 1.75 mg subcutaneously for the approved indication, no more than once per 24 hours and no more than eight times per month [7]. That figure describes the approved drug under medical supervision; this page documents it and recommends no amount to any reader.

## What is the PT-141 dosage for women?

The only FDA-approved PT-141 dosage for women is 1.75 mg subcutaneous as-needed for premenopausal women with HSDD [7]. This is the dose tested in the RECONNECT Phase 3 trials [3]. The approval does not extend to postmenopausal women [9].

## How do you reconstitute PT-141?

The FDA-approved bremelanotide product is supplied as a ready-to-use prefilled autoinjector, so the approved drug is not reconstituted by the user [7]. "Research chemical" PT-141 is unregulated and not the approved product; this site does not provide preparation instructions for unapproved material [7].

## How do you take PT-141?

For the approved drug, the label specifies a subcutaneous injection taken as needed at least 45 minutes before anticipated activity, no more than once per 24 hours [7]. This describes the approved indication under a prescriber's care; this page documents the label and gives no personal instruction.

## How often can you take PT-141?

The label limits bremelanotide to one dose per 24 hours and no more than eight doses per month [7]. In the 52-week extension of RECONNECT (684 women), no new safety signals emerged at that frequency, and nausea (40.4%) was the most common drug-related effect [4].

---

An azure-ruled ledger of the PT-141 (bremelanotide) record — the 2019 approval, the 1,267-woman trials, and the half-life on the label entered as cited credits, with the small-effect critique, the ~40% nausea, and the premenopausal-HSDD-only boundary ruled in plain sight as the debits they are; no clinic balances behind this page and nothing here is dosed, prescribed, or sold.